Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1 clinical trials
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

body mass index
moxonidine
ace inhibitor
amlodipine 5 mg
hypertension
  • 0 views
  • 19 Feb, 2024